BioGaia AB Interim report 1 January - 30 September 2011
(Figures in brackets refer to the same period of last year)
Interim period, 1 January - 30 September 2011
- Net sales reached SEK 232.6 million (173.3), an increase of SEK 59.3
million (34%). Excluding foreign exchange effects, the increase in net sales was
43%1).
- Operating profit was SEK 79.4 million (40.1)2), an improvement of SEK 39.3
million (98%). Excluding foreign exchange effects, operating profit rose by
121%1).
- Profit before tax was SEK 79.2 million (51.1) 2), an increase of SEK 28.1
million (55%). Net financial items include a foreign exchange effect of SEK -2.2
million (+10.5) arising from foreign exchange contracts in EUR.
- Profit after tax was SEK 57.8 million (34.3) 2), an improvement of SEK
23.5 million (69%).
- Earnings per share amounted to SEK 3.24 (1.99).
- Total cash flow was SEK 14.2 million (25.7). During the period BioGaia paid
dividends of SEK 34.5 million and corporate tax of SEK 30.1 million (of which
SEK 18.4 million refers to the financial year 2010). Cash and cash equivalents
at 30 September 2011 totalled SEK 161.4 million (125.7).
Third quarter, 1 July - 30 September 2011
- Net sales reached SEK 73.1 million (48.9), an increase of SEK 24.2 million
(49%). Excluding foreign exchange effects net sales were up by 53%1).
- Operating profit was SEK 22.1 million (8.6)2), an improvement of SEK 13.5
million (157%). Excluding foreign exchange effects, operating profit increased
by 160%1).
- Profit before tax was SEK 21.4 million (12.9) 2), an increase of SEK 8.5
million (66%). Net financial items include a foreign exchange effect of SEK -1.5
million (+3.9) arising from foreign exchange contracts in EUR.
- Profit after tax was SEK 15.6 million (8.0) 2), an improvement of SEK 7.6
million (95%).
Key events in the third quarter of 2011
- Agreement for the sale of drops and tablets in Morocco.
- Agreement for the sale of tablets in the USA.
- Agreement for the sale of tablets in the Philippines.
Key events after the end of the third quarter
- Agreement for the sale of drops and tablets in Venezuela and Puerto Rico.
"We are extremely pleased to note continued excellent growth in sales for both
of our product segments. Due to the summer holiday in Europe, the third quarter
is normally our weakest period in terms of sales. Thanks to a few substantial
orders from Nestlé, however, the third quarter was unusually strong." says Peter
Rothschild, President of BioGaia.
BioGaia is a biotechnology company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic,
health-enhancing effects. The class B share of the Parent Company
BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange
Stockholm. www.biogaia.com
[HUG#1557512]
